USS Investment Management Ltd Purchases New Shares in BioNTech SE (NASDAQ:BNTX)

USS Investment Management Ltd bought a new position in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 27,850 shares of the company's stock, valued at approximately $3,117,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jones Financial Companies Lllp lifted its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its stake in shares of BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after buying an additional 700 shares during the last quarter. Allianz SE bought a new position in shares of BioNTech during the fourth quarter valued at about $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech during the fourth quarter valued at about $137,000. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of BioNTech during the fourth quarter worth about $168,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on BNTX shares. Morgan Stanley lowered their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday. They issued a "neutral" rating and a $110.00 target price for the company. JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $140.14.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded up $1.63 during midday trading on Thursday, reaching $99.16. The company's stock had a trading volume of 181,273 shares, compared to its average volume of 915,422. The firm has a market capitalization of $23.84 billion, a PE ratio of -47.22 and a beta of 1.35. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The stock has a fifty day moving average of $97.48 and a 200 day moving average of $108.24. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 earnings per share. On average, equities analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.